NCT04243447 (DoD FAI-2) is a clinical trial in Femoracetabular Impingement, sponsored by Washington University School of Medicine.

Who is sponsoring NCT04243447?

NCT04243447 is sponsored by Washington University School of Medicine.

What condition does NCT04243447 study?

NCT04243447 studies Femoracetabular Impingement.

Is NCT04243447 still recruiting?

NCT04243447 is currently active, enrolled. Last updated 3 October 2025.

Last reviewed 2025-10-03 · How we verify

NCT04243447: DoD FAI-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery

Active, enrolled Last updated 3 October 2025

What this trial tests

trial in Femoracetabular Impingement in 747 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 February 2020

Primary endpoint
29 November 2025

29 November 2025

Quick facts

Lead sponsor	Washington University School of Medicine
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	747
Start date	2 February 2020
Primary completion	29 November 2025
Estimated completion	29 November 2025
Sites	13 locations across Canada, United States

Conditions studied

Femoracetabular Impingement — all drugs for Femoracetabular Impingement →

Sponsor

Washington University School of Medicine

Who can join

Adults 14 to 40, any sex, with Femoracetabular Impingement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching goal of the study is to improve the surgical treatment outcomes of FAI, which is affecting an increasing number of military personnel and young active individuals in the general population. The proposed study will investigate critical patient, disease, and surgical treatment predictors of FAI surgery outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04243447 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 3 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04243447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing